Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Joel Hecht (ucla)

Description

Summary

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients.

Official Title

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, As Monotherapy and in Combination with Pembrolizumab, Cetuximab or FOLFIRI Plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies

Details

TTX-080 is a fully human mAb designed to block the interaction of HLA-G with its known ligands, ILT2 and ILT4 molecules. The Phase 1a was an open label, multicenter, dose escalation clinical trial to determine the safety, tolerability, MTD or OBD, and the RP2D of TTX-080 when administered as a single agent. The Phase 1b is a dose expansion of TTX-080 monotherapy and in combination with either pembrolizumab or cetuximab in adult subjects with advanced refractory/resistant solid malignancies, including Head and Neck squamous cell carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Colorectal cancer (CRC), triple negative breast cancer (TNBC), renal cell carcinoma (RCC), and acral melanoma. Additionally, the Phase 1b includes randomized arms with TTX-080 in combination with FOLFIRI plus cetuximab compared to FOLFIRI plus cetuximab in metastatic Colorectal cancer. The study will seek to evaluate the pharmacokinetics and immunogenicity of TTX-080, and characterize the anti-tumor activity of TTX-080 as a monotherapy and in combination with pembrolizumab, cetuximab or FOLFIRI plus cetuximab.

Keywords

Cancer, HLA-G, TTX-080, Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Kidney Cancer, Head and Neck Squamous Cell Carcinoma, Squamous Cell Lung Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancer, Breast Cancer, Bladder Cancer, Lung Adenocarcinoma, Melanoma, Metastatic Solid Tumor, Renal cell carcinoma, Acral melanoma, Triple Negative Breast Cancer, Pembrolizumab, Cetuximab, Antineoplastic Agents, Immunological, Antineoplastic Agents, Head and Neck Cancer, Lung Cancer, FOLFIRI, FOLFIRI plus cetuximab

Eligibility

For people ages 18 years and up

Abbreviated Inclusion Criteria:

  1. Subject with histological diagnosis of advanced/metastatic cancer
  2. Age 18 years or older, is willing and able to provide informed consent
  3. Evidence of measurable disease
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 AND life expectancy of at least 12 weeks

Abbreviated Exclusion Criteria:

  1. History of allergy or hypersensitivity to study treatment components. Subjects with a history of severe hypersensitivity reaction to any monoclonal antibody
  2. Use of an investigational agent within 28 days prior to the first dose of study treatment and throughout the study
  3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy
  4. History of severe autoimmune disease
  5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment

Locations

  • Hoag Memorial Hospital completed
    Newport Beach California 92663 United States
  • University of Southern California in progress, not accepting new patients
    Los Angeles California 90033 United States
  • Arizona Oncology Associates accepting new patients
    Tucson Arizona 85711 United States
  • Rocky Mountain Cancer Centers accepting new patients
    Denver Colorado 80218 United States

Lead Scientist at University of California Health

  • Joel Hecht (ucla)
    Dr. Joel R. Hecht holds the Carol and Saul Rosenzweig Endowed Chair for Cancer Therapies Development.

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Tizona Therapeutics, Inc
ID
NCT04485013
Phase
Phase 1 Cancer, General Research Study
Study Type
Interventional
Participants
Expecting 240 study participants
Last Updated